Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

The experience at Meta seems to confirm what some of us have long argued. Yielding to those who demand censorship only produces an insatiable appetite for more speech curtailment.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Duolingo CEO and cofounder Luis von Ahn just made a statement on AI tools at his company, saying that he doesn’t “see AI as replacing what our employees do.” This view certainly appears to be a ...

Array Technologies, a global provider of solar tracking technology products, expanded its SmarTrack software to include backtracking and diffuse optimization capabilities for its Array STI H250 ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...